Cognitive Training Intervention and Attitudes Towards Genetics
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Lumosity, Lumosity (waitlist control).
- Who it may be relevant to
- Registry conditions: Cognitive Impairment, Hematologic Neoplasms, Hematopoietic Cell Transplant. Basic parameters: from 21 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Intervention Strategies to Improve Cognitive Functioning in Hematologic Cancer Survivors After Hematopoietic Cell Transplantation
Overview
A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured.
Detailed description
The investigators propose using an "off-the-shelf" product - Lumosity (http://www.lumosity.com/) - an online cognitive training program, to address the cognitive impairment in outpatient HCT survivors. The program offers over 60 tasks in game-like format that cover the main cognitive domains: processing speed, working memory, and executive function. Training will involve a daily session of 5 training tasks for 12 weeks. Each time the patient is logged in for a session, a customized report will be generated by the Lumosity program to capture performance information.
Ideally, targeting the intervention and offering it specifically to those at highest risk (integrating clinical and genetic markers) would ensure efficacy. However, evidence is lacking on whether patients are receptive to communication of individual genetic information and whether provision of such results would lead to enhanced intervention response. To realize the high expectations of personalized medicine, patients' preferences and attitudes need to be thoroughly investigated especially as more information on genetic risk becomes available. The investigators will examine patients' genetic knowledge to determine whether factual knowledge of genetics is essential for understanding genetic risk and for informing treatment decision making in this patient population.
Interventions
- Behavioral Lumosity
Computer-based online cognitive training program using the Lumosity cognitive training program. - Behavioral Lumosity (waitlist control)
Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
Primary outcome measures
- Number of HCT patients completing the 2-arm wait-listed randomized trial of cognitive training intervention for a period of 3 months [Time frame: 12 weeks]
- Change in cognitive function between intervention and wait list control arms from baseline to 12 weeks. [Time frame: Baseline to 12 weeks]
Secondary outcome measures (5)
- 16-item survey to measure genetic factual knowledge at baseline [Time frame: Baseline]
- Effect size of associations of key predictors with genetic factual knowledge at baseline [Time frame: Baseline]
- 5 Likert scale survey questionnaire to measure importance of receiving genetic risk information [Time frame: baseline]
- 5 Likert scale survey questionnaire to measure impact of receiving genetic risk information on intervention uptake [Time frame: baseline]
- 5 Likert scale survey questionnaire to measure impact of receiving genetic risk information on intervention adherence [Time frame: baseline]
Eligibility criteria
Inclusion criteria
- ≥ 21 years old at time of allogeneic HCT performed at UAB
- Outpatient and between 3 and 6 months post HCT
- English speaking
- Possess access to an internet-connected home computer
Exclusion criteria
- History of pre-existing neurological disorder or documented major psychiatric disorder; significant auditory, visual, or motor impairments
- Participated in neuropsychological intervention within the past 6 months
- History of color blindness
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Supportive care
Study locations
United States · 1 center
- University of Alabama at Birmingham — Birmingham
Identifiers
NCT: NCT03094026 · X161221006